Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Haloperidol

Drug and asset intelligence for Haloperidol with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Alembic Pharmaceuticals →

Recent signals(2)

RegulatoryAugust 17, 2026

FDA Approval Status for Haloperidol ANDA071130 by AIPING PHARM INC.

The FDA has an active application (ANDA071130) for Haloperidol submitted by AIPING PHARM INC., currently under AP status. This application indicates that AIPING PHARM INC. is seeking to introduce a generic version of Haloperidol, a well-established antipsychotic medication.

StrategyJune 30, 2026

FDA Grants Approval for Haloperidol ANDA214470 by Alembic

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 214470 for Haloperidol submitted by Alembic.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Alembic Pharmaceuticals — Haloperidol

June 30, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Antipsychotic →

Psychiatry · Antipsychotic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.